Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study)
PURPOSE: Hyperkalemia is a common metabolic complication of chronic kidney disease (CKD) and is associated with several serious adverse events. We aimed to treat/prevent hyperkalemia using the new of potassium-binders, allowing maintained renin-angiotensin-aldosterone system inhibitors (RAASi) treat...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027611/ https://www.ncbi.nlm.nih.gov/pubmed/36960344 http://dx.doi.org/10.2147/IJNRD.S401623 |
_version_ | 1784909741501186048 |
---|---|
author | Bjune, Thea Bøe, Thea Bjerkestrand Kjellevold, Stig Arne Heldal, Kristian Abedini, Sadollah |
author_facet | Bjune, Thea Bøe, Thea Bjerkestrand Kjellevold, Stig Arne Heldal, Kristian Abedini, Sadollah |
author_sort | Bjune, Thea |
collection | PubMed |
description | PURPOSE: Hyperkalemia is a common metabolic complication of chronic kidney disease (CKD) and is associated with several serious adverse events. We aimed to treat/prevent hyperkalemia using the new of potassium-binders, allowing maintained renin-angiotensin-aldosterone system inhibitors (RAASi) treatment in proteinuric CKD and/or congestive heart failure (CHF) patients. PATIENTS AND METHODS: We conducted a retrospective cohort study in long-term users of potassium binders for chronic hyperkalemia. Patients aged 18 years and older, treated with potassium-binders and who met the reimbursement criteria and indication for RAASi treatment were included. RESULTS: Fifty-seven percent of the patients were males and mean age was 65 years. During the study period, no patients were admitted to hospital due to hyperkalemia after initiation of potassium binders. Potassium maximum values were significantly lower after treatment. Few patients reported major side effects, and discontinuation was mostly due to normokalemia. We found no significant changes in bicarbonate, serum creatinine or GFR stage after starting potassium binder treatment. All patients on RAASi treatment before initiating potassium-binders were retained on RAASi treatment. CONCLUSION: New potassium binders in clinical practice are an easy and safe treatment with few side effects and good tolerance, that significantly lowers the risk of hyperkalemia. Furthermore, and most importantly, patients can be maintained on RAASi treatment. |
format | Online Article Text |
id | pubmed-10027611 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-100276112023-03-22 Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) Bjune, Thea Bøe, Thea Bjerkestrand Kjellevold, Stig Arne Heldal, Kristian Abedini, Sadollah Int J Nephrol Renovasc Dis Original Research PURPOSE: Hyperkalemia is a common metabolic complication of chronic kidney disease (CKD) and is associated with several serious adverse events. We aimed to treat/prevent hyperkalemia using the new of potassium-binders, allowing maintained renin-angiotensin-aldosterone system inhibitors (RAASi) treatment in proteinuric CKD and/or congestive heart failure (CHF) patients. PATIENTS AND METHODS: We conducted a retrospective cohort study in long-term users of potassium binders for chronic hyperkalemia. Patients aged 18 years and older, treated with potassium-binders and who met the reimbursement criteria and indication for RAASi treatment were included. RESULTS: Fifty-seven percent of the patients were males and mean age was 65 years. During the study period, no patients were admitted to hospital due to hyperkalemia after initiation of potassium binders. Potassium maximum values were significantly lower after treatment. Few patients reported major side effects, and discontinuation was mostly due to normokalemia. We found no significant changes in bicarbonate, serum creatinine or GFR stage after starting potassium binder treatment. All patients on RAASi treatment before initiating potassium-binders were retained on RAASi treatment. CONCLUSION: New potassium binders in clinical practice are an easy and safe treatment with few side effects and good tolerance, that significantly lowers the risk of hyperkalemia. Furthermore, and most importantly, patients can be maintained on RAASi treatment. Dove 2023-03-16 /pmc/articles/PMC10027611/ /pubmed/36960344 http://dx.doi.org/10.2147/IJNRD.S401623 Text en © 2023 Bjune et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Bjune, Thea Bøe, Thea Bjerkestrand Kjellevold, Stig Arne Heldal, Kristian Abedini, Sadollah Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) |
title | Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) |
title_full | Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) |
title_fullStr | Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) |
title_full_unstemmed | Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) |
title_short | Hyperkalemia and the Use of New Potassium Binders a Single Center Experience from Vestfold Norway (The PotBind Study) |
title_sort | hyperkalemia and the use of new potassium binders a single center experience from vestfold norway (the potbind study) |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027611/ https://www.ncbi.nlm.nih.gov/pubmed/36960344 http://dx.doi.org/10.2147/IJNRD.S401623 |
work_keys_str_mv | AT bjunethea hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy AT bøetheabjerkestrand hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy AT kjellevoldstigarne hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy AT heldalkristian hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy AT abedinisadollah hyperkalemiaandtheuseofnewpotassiumbindersasinglecenterexperiencefromvestfoldnorwaythepotbindstudy |